Retrovirus-mediated gene transfer in cancer therapy
ABSTRACT Retroviral vectors are one of the most promising systems for the transfer and the expression of therapeutic genes in human gene therapy protocols. This review will focus both on the advantages and intricacies of retroviral vectors themselves as well as on the application of these vector systems in experimental and clinical cancer therapy protocols. Therefore, the retrovirus life cycle and the general features of retroviral vectors, including possible targeting strategies with retroviral vectors, are overviewed. These topics are followed by the presentation of genes with emphasis on their potential as tools in somatic cell cancer therapy (cytokines, lymphokines, colony-stimulating growth factors, suppressor genes, antisense oncogenes, suicide genes). Finally, a prospect on the application of retroviral vectors will be described.
SourceAvailable from: Brendan M Duggan
Patent: Secreted Proteins[Show abstract] [Hide abstract]
ABSTRACT: The invention provide human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonsits, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.Ref. No: US7608704, Year: 10/2009
[Show abstract] [Hide abstract]
ABSTRACT: Abstract Abstract Abstract Abstract Abstract AIM:T o investigate the effect of bromocriptine(BCT) and tumor necrosis factor-α(TNF- α) on hepatocellular carcinoma (HCC) multidrug resistance (MDR) in nude mouse MDR model of liver neoplasm. METHODS: Human hepatocarcinoma cell line HepG2, drug
Neurosurgical FOCUS 04/2000; 8(4):1-7. DOI:10.3171/foc.2000.8.4.3 · 2.14 Impact Factor